47,000 Shares in BioMarin Pharmaceutical Inc. $BMRN Acquired by Elmind Capital LP

Elmind Capital LP purchased a new stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 47,000 shares of the biotechnology company’s stock, valued at approximately $2,689,340,000. BioMarin Pharmaceutical makes up approximately 0.7% of Elmind Capital LP’s investment portfolio, making the stock its 26th biggest position.

A number of other hedge funds have also added to or reduced their stakes in BMRN. Activest Wealth Management bought a new stake in shares of BioMarin Pharmaceutical in the fourth quarter worth $26,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in BioMarin Pharmaceutical in the second quarter valued at about $39,000. CIBC Private Wealth Group LLC boosted its position in BioMarin Pharmaceutical by 38.2% in the fourth quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company’s stock worth $39,000 after purchasing an additional 179 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in shares of BioMarin Pharmaceutical during the 3rd quarter valued at about $40,000. Finally, Parallel Advisors LLC increased its position in shares of BioMarin Pharmaceutical by 62.2% during the 3rd quarter. Parallel Advisors LLC now owns 769 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 295 shares during the last quarter. 98.71% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on BMRN shares. The Goldman Sachs Group started coverage on shares of BioMarin Pharmaceutical in a report on Monday, May 11th. They issued a “neutral” rating and a $69.00 price objective on the stock. HC Wainwright cut their price target on BioMarin Pharmaceutical from $60.00 to $59.00 and set a “neutral” rating for the company in a research note on Tuesday, August 18th. Citigroup lifted their price objective on shares of BioMarin Pharmaceutical from $75.00 to $76.00 and gave the company a “buy” rating in a research report on Thursday, July 16th. Wall Street Zen upgraded BioMarin Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Finally, Barclays increased their price objective on shares of BioMarin Pharmaceutical from $105.00 to $111.00 and gave the company an “overweight” rating in a research report on Monday, August 17th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $88.83.

BioMarin Pharmaceutical Stock Up 1.6%

Shares of NASDAQ BMRN opened at $66.12 on Wednesday. The stock’s fifty day simple moving average is $61.07 and its two-hundred day simple moving average is $57.99. BioMarin Pharmaceutical Inc. has a 12-month low of $49.26 and a 12-month high of $70.98. The company has a current ratio of 2.39, a quick ratio of 1.32 and a debt-to-equity ratio of 0.56. The stock has a market capitalization of $12.80 billion, a PE ratio of 178.70, a price-to-earnings-growth ratio of 0.47 and a beta of 0.24.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, topping the consensus estimate of $0.95 by $0.25. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.32%. The firm had revenue of $989.71 million during the quarter, compared to analyst estimates of $932.03 million. During the same quarter in the previous year, the business posted $1.44 EPS. BioMarin Pharmaceutical’s revenue was up 20.0% on a year-over-year basis. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. As a group, analysts expect that BioMarin Pharmaceutical Inc. will post 4.1 EPS for the current fiscal year.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.